Table 1: Clinical characteristics, treatments and outcomes of patients with hematological malignancies and SARS-CoV-2 infection.
|
Patient No |
Age |
Sex |
Hematological disease |
Hematological treatment |
Comorbidities |
ARDS |
Invasive mechanical ventilation |
Survival status |
|
1 |
70 |
F |
MPN |
Ruxolitinib |
cardiomiophaty |
no |
no |
Alive |
|
2 |
60 |
F |
MPN |
Hu |
no |
no |
no |
Alive |
|
3 |
49 |
M |
MPN |
Hu |
no |
no |
no |
Alive |
|
4 |
77 |
M |
MPN |
Hu |
Diabetes and cardiomiopathy |
no |
no |
Alive |
|
5 |
54 |
M |
LNH |
Rituximab maintenance |
no |
no |
no |
Alive |
Abbreviation: M: Male; F: Female; HU: Hydroxyurea; MPN: Philadelphia Negative Disorders; LNH: Non-Hodgkin Lymphoma